Abstract
Background and Aims: Evolocumab, a fully human monoclonal antibody directed against proprotein convertase subtilisin/kexin type 9, has been show to lower plasma low-density lipoprotein cholesterol (LDL-C) in pediatric patients with familial hypercholesterolemia (FH). Here, we report on the effect of evolocumab on cognitive function in pediatric patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
